Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avricore Health (AVCRF) Research & Development (2016 - 2025)

Historic Research & Development for Avricore Health (AVCRF) over the last 17 years, with Q3 2025 value amounting to $8691.3.

  • Avricore Health's Research & Development rose 124730.77% to $8691.3 in Q3 2025 from the same period last year, while for Sep 2025 it was $99906.9, marking a year-over-year increase of 4363.77%. This contributed to the annual value of $69634.8 for FY2024, which is 16602.78% up from last year.
  • Latest data reveals that Avricore Health reported Research & Development of $8691.3 as of Q3 2025, which was up 124730.77% from $16206.1 recorded in Q2 2025.
  • In the past 5 years, Avricore Health's Research & Development ranged from a high of $44599.5 in Q1 2024 and a low of $92.15 during Q3 2021
  • In the last 5 years, Avricore Health's Research & Development had a median value of $8691.3 in 2025 and averaged $12991.0.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 1195224.16% in 2022, then tumbled by 8883.97% in 2024.
  • Over the past 5 years, Avricore Health's Research & Development (Quarter) stood at $10257.0 in 2021, then plummeted by 50.84% to $5042.7 in 2022, then tumbled by 41.31% to $2959.4 in 2023, then soared by 1353.69% to $43021.1 in 2024, then plummeted by 79.8% to $8691.3 in 2025.
  • Its Research & Development stands at $8691.3 for Q3 2025, versus $16206.1 for Q2 2025 and $31988.5 for Q1 2025.